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Abstract—Mobile applications are being used to perform a wide
variety of tasks in day-to-day life ranging from checking email, to
controlling your home heating. Application developers have
recognized the potential to transform a smart device into a medical
device, by using a mobile medical application i.e. a mobile phone or
a tablet. When initially conceived these mobile medical applications
performed basic functions e.g. BMI calculator, accessing reference
material etc.; however, increasing complexity offers clinicians and
patients a range of functionality. As this complexity and functionality
increases, so too does the potential risk associated with using such an
application. Examples include any applications that provide the
ability to inflate and deflate blood pressure cuffs, as well as
applications that use patient-specific parameters and calculate dosage
or create a dosage, plan for radiation therapy. If an unapproved
mobile medical application is marketed by a medical device
organization, then they face significant penalties such as receiving an
FDA warning letter to cease the prohibited activity, fines and
possibly face criminal conviction.
Regulatory bodies have finalized guidance intended for mobile
application developers to establish if their applications are subject to
regulatory scrutiny. However, regulatory controls appear
contradictory with the approaches taken by mobile application
developers who generally work with short development cycles and
very little documentation and as such, there is the potential to stifle
further improvements due to these regulations. The research
presented as part of this paper details how by adopting development
techniques such as agile software development, mobile medical
application developers can meet regulatory requirements whilst still
fostering innovation.
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I. INTRODUCTION

I

N early 2009, Apple first demonstrated how mobile devices
could be used in connection with medical devices. At their
annual World Wide Developer Conference they connected
blood pressure monitors and blood glucose meters to an
IPhone via Bluetooth and cable [1]. In 2014, a report was
released which stated that there are over 100,000 Mobile
Medical Applications (MMA) available on the two major
mobile platforms, IOS and Android. The same report stated
that this market was worth $4 billion and this could potentially
rise to as much $26 billion by 2017 [2]. Evidence of this
growing popularity can be seen by the major platform
providers who are not simply supporting these applications
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(apps), but they are now integrating these apps directly with
their operating systems e.g. Google Fit, Health from Apple
and Microsoft Health.
MMAs typically meet the definition of being mHealth i.e.
“the use of wireless communication to support efficiency in
public health and clinical practice” [3]. Furthermore, by their
very nature, MMAs are deemed as medical device software.
Medical device software can be:
• Standalone software;
• Embedded software;
• Software, which transforms a device into a regulated
medical device.
To accompany this, research has shown that not only are
these apps being developed at a high rate, but also clinicians
worldwide are adopting them. In 2015, approximately 500
million people used mobile medical applications [4]-[5].
With MMAs becoming increasingly prevalent, regulatory
bodies determined that regulations or guidance was needed for
app developers to establish if they required regulatory
approval prior to being marketed for use [6]. Within the
United States (US), the Food and Drug Administration (FDA)
regulate medical devices and within the European Union (EU),
medical device regulations are created by the European
Council and enforced by notified bodies within each member
state.
The first step in regulating MMAs was the release of the
FDA Final Rule on Medical Device Data Systems (MDDS).
This rule aimed to provide clear guidance as to when software
or devices could be deemed as Class I devices and would
require the lowest level regulatory scrutiny. However,
confusion remained amongst apps developers if their app did
not meet the definition of being a MDDS or a MMA. To
provide further guidance, the FDA released its draft guidance
for mobile medical application developers in 2011 with the
final version of this guidance document being released in
2015. The aim of this document was to remove ambiguity
surrounding the regulation of MMA.
In the past, app development organizations who have
attempted to innovate and revolutionize the healthcare
industry through MMAs, have been stifled by regulations
leading to a reluctance to other manufacturers to enter the
market [7]. One of the key advantages to mobile applications
is that development costs are typically low as the application
is not as complete as a fully-fledged software application [8].
Mobile application manufacturers typically do not produce
comprehensive documentation and do not develop their apps
in accordance with any defined software development
technique. Whilst this approach may be acceptable when

developing traditional mobile applications, it is not acceptable
for developing MMAs, as regulatory bodies require
comprehensive documentation as evidence of the safety and
efficacy of the application.
Agile software development techniques have been adopted
by traditional app development organizations. Agile methods
offer reduced development costs, improved time to market and
a shorter development lifecycle [9]. However, research has
revealed a slow rate of adoption of agile methods by
organizations developing software for use in the medical
domain [10]. Where agile methods have been adopted for
developing software for use in the medical domain, the
organizations involved have reported significant benefits [11],
[12].
The remainder of this paper is structured as follows: section
2 provides background to the approach taken by regulatory
bodies with regards the use of software in a healthcare
environment; section 3 explains further what a mobile medical
application is in terms of how is its viewed by regulatory
bodies; section 4 discusses how software development
techniques such as agile software development can be used to
achieve regulatory deliverables whilst fostering innovation
when developing MMAs and section 5 provides the
conclusions derived from this research.
II. BACKGROUND
A. Regulations
In 1981, the FDA began to investigate the use of software in
healthcare. Initially, the FDA classified medical device
software based upon its Draft Software Policy published in
1987 and revised in 1989 [13]. However, the FDA recognised
that as the rate of computer and software-based products was
growing at an exponential rate, it was not practical to adopt a
single “software” policy, which would cover all computer and
software based products. Consequently, the draft software
policy was withdrawn in January 2005 [14]. As a result, the
FDA does not specifically regulate software; rather it regulates
devices used in healthcare, which meet the definition of being
a medical device. The FDA definition of what constitutes a
medical device is outlined in section 201(h) of the Federal
Food Drug & Cosmetic (FD&C) Act [15].
"an instrument, apparatus, implement, machine,
contrivance, implant, in vitro reagent, or other similar or
related article, including a component part, or accessory
which is:
• recognized in the official National Formulary, or the
United States Pharmacopoeia, or any supplement to
them,
• intended for use in the diagnosis of disease or other
conditions, or in the cure, mitigation, treatment, or
prevention of disease, in man or other animals, or
• intended to affect the structure or any function of the
body of man or other animals, and which does not
achieve its primary intended purposes through
chemical action within or on the body of man or
other animals and which is not dependent upon

being metabolized for the achievement of any of its
primary intended purposes."
It can be seen from the definition provided that if software
performs any of the functions outlined in the definition of a
medical device, then it becomes subject to scrutiny by the
FDA.
1) Safety Classification
All medical devices marketed for use within the US must
receive a safety classification. This classification is
determined based upon the potential risk a medical device
poses on patients, clinicians or third parties. The three
classifications are, Class I Low Risk, Class II Medium Risk
and Class III High Risk. All medical devices initially receive a
Class III safety classification unless they meet the definition of
being in a device category with a lower classification or until
they are reclassified by the FDA.
2) 21 CFR 820 Quality Systems Regulations
All medical devices marketed for use within the US
regardless of device safety classification, must provide
evidence of adoption of a Quality Management System
(QMS), such as in accordance with 21 CFR 820 Quality
Systems Regulations (QSR) [16] and the FDA Design Control
Guidance for Medical Device Manufacturers [17]. Of note
within the QSR is Subpart C – Design Controls, which
provides information as to which processes must be adhered to
when developing regulatory compliant software. These
include:
• Design & Development Planning (Specifications);
• Design Output (Coding);
• Design Review;
• Design Verification (Was the Product Built Right?);
• Design Validation (Was the Right Product Built?).
The primary objective of the QSR is to ensure the safe and
reliable performance of a medical device. A device is deemed
safe if it does not cause harm to a patient, clinician or third
party and it is deemed reliable if it performs the desired
function each and every time it is used.
3) 21 CFR 880 Medical Devices; Medical Device Data
Systems Final Rule
Prior to April 16th 2011, devices that now meet the current
definition of being a MDDS were classified as either a Class
III device, or assumed the safety classification of the parent
medical device to which they were connected, although the
FDA had been operating under their discretionary enforcement
policy and therefore was not enforcing the Class III
requirements on all MDDS. However, on April 16th 2011, a
FDA rule became effective which classified a MDDS device
as Class I, 510 (k) exempt - medical device [14]. This ruling
came three years after the proposed ruling was issued on
February 8th 2008. This final classification modifies FDA 21
C.F.R § 880.6310 and describes a MDDS as being:
“software, electronic, or electrical hardware such as
a physical communications medium (including wireless

hardware), modems, interfaces and communications
protocol”
The FDA provided the following definition of what
constitutes a MDDS:
“A device that is intended to provide one or more of
the following uses, without controlling or altering the
functions or parameters of any connected medical
devices:
(i) The electronic transfer of medical device data;
(ii) The electronic storage of medical device data;
(iii) The electronic conversion of medical device data
from one format to another format in accordance
with a pre-set specification; or
(iv) The electronic display of medical device data.”
There is however, an exception to this rule. If software
exclusively performs one or more of the functions outlined in
the definition of a MDDS and is used for active patient
monitoring, then it cannot be considered a MDDS and must be
considered an accessory or medical device in its own right.
B. Standards
In November 1997, the FDA signed into law the
Modernization act, known as the Food and Drug
Administration Modernization Act (FDAMA) [18]. A key
element of FDAMA is the advocating of the use of standards
in the design review process. To support the FDAMA, the
FDA published in the Federal Register, a list of standards to
which medical device manufacturers could declare
conformity. A key objective of the FDAMA was to reduce the
burden on both the FDA and medical device manufacturers by
reducing the regulatory obstacle to entry to international and
domestic medical device markets. When the FDAMA was
signed into law, the Centre for Devices and Radiological
Health (CDRH) established Standards Technology Groups
(STG), one of which had a specific focus on software. A STG
is responsible for software categorized as follows:
• General process standards, which are technology
independent;
• General process standards, which are technology
dependent;
• Specific process implementations.
A number of standards are included on the Federal Register
list of standards; of most significance with regards to medical
device software development is IEC 62304:2006 Medical
Device – Software Life Cycle Processes [19]. Also of
significance to medical device software and all types of
medical device is ISO 14971:2012 Application of Risk
Management to Medical Devices [20]. In the EU, ISO
13485:2012 [21] Medical Devices – Quality Management
Systems – Requirements for Regulatory Purposes is central to
the development of regulatory compliant software. However,
prior to March 2012, medical device companies wishing to
market a medical device within the US were required to
provide evidence of adherence to the FDA QSR regulations.
Therefore, if a medical device manufacturer was developing a
medical device for use in the EU and the US, they needed to
conform to both of the quality management system guidelines.

In March 2012, the FDA commenced a pilot program offering
device manufacturers the option of submitting their quality
system audits, which are compliant with ISO/IEC 13485:2012,
to the FDA’s Centre for Devices and Radiological Health
(CDRH) or Centre for Biologics Evaluation and Research
(CBER) [22]. This is seen as a step forward in the FDA’s plan
to create a partnership with Health Canada, which would
result in a single audit program for both the US and Canada.
1) IEC 62304:2006 Medical Device – Software Life Cycle
Processes
As medical devices are safety critical, manufacturers are
recommended to follow current international standards during
development. Adherence to these standards is not mandatory,
but it is recommended in order to achieve regulatory approval.
Adherence to the standards demonstrates the manufacturer’s
ability to follow defined development procedures and to
perform the required risk management activities [23]. If a
manufacturer chooses not to adhere to these standards, they
must provide a sufficient explanation as to why and they must
demonstrate that the alternative method chosen is equally
valid. Within the US, it is the responsibility of the FDA to
ensure compliance with these standards. FDA auditors and
Inspectors perform these compliance checks.
IEC 62304:2006 is the current software development
standard followed by medical device software developers. The
current version of IEC 62304 was released in 2006. IEC 62304
is derived from ISO/IEC 12207:1995 Software Lifecycle
Processes [24], AMD 1:2002 [25] and 2:2004 [26]. ISO
12207:1995 is not domain specific but it is seen as being
comprehensive in its approach which is reflected in the
number of standards that utilize the core principles of ISO
12207:1995, AMD 1 and AMD 2 as their foundation such as
ISO/IEC 15504-5:2006. IEC 62304 is domain specific and is
tailored to suit the specific requirements of the medical device
software development industry. IEC 62304 is a software
development standard that provides end-to-end guidance in the
development of the software component of a medical device.
However, it hands off system activities such as Requirements
Elicitation and Validation, to its aligned standards which
include ISO 13485:2003 Medical Devices – Quality
Management Systems [27], ISO 14971:2007 Medical Devices
– Application of Risk [28] and ISO/IEC 15288:2008 –
Systems and Software engineering – System lifecycle
processes [29]. IEC 62304 is a harmonized standard under the
MDD [30] and is a FDA consensus standard [31].
IEC 62304 makes provision for the application of risk to
software. IEC 62304 applies a classification system to
software components similar to that of ISO 14971 Clause
4.4.5 and 6.1. The safety classification is as follows:
• Class A – No injury or damage to health possible;
• Class B – Non-serious injury is possible;
• Class C – Death or serious injury is possible.
The risk classification applied to an item of software is
determined by the amount of potential risk the medical device
places upon the patient, clinician or third party. With IEC
62304, the overall software component assumes the safety

classification of the software element that poses the most risk.
However, IEC 62304 does make allowance for software
components to be segregated into individual software elements
with each element receiving its own safety classification.
2) ISO 13485:2012 Medical Devices – Quality Management
Systems – Requirements for Regulatory Purposes
ISO 13485:2012 was published in 2012, which forms the
basis for the development of a quality management system
when developing medical device software. ISO 13485 is
derived from ISO 9001; however, ISO 13485 is tailored to
include elements specific to the development of medical
devices. Additionally, ISO 9001 requires a device
manufacturer to perform continuous improvement, while ISO
13485 only requires a manufacturer to implement and
maintain a quality management system. As previously
discussed, the FDA now accepts quality management audits
performed in accordance with ISO 13485.
3) ISO 14971:2012 – Application of Risk Management to
Medical Devices
ISO 14971 was first released in 2000 with the second
edition released in 2007 and the latest version released in
2012. ISO 14971 is a FDA consensus standard. It specifies the
procedures and activities for identifying hazards in medical
devices and accessories to medical devices, including
software. ISO 14971 provides guidelines to medical device
manufacturers on the preparation of a plan to prepare for risk
management activities. The plan should contain:
• The scope of the plan;
• A verification plan;
• Allocation of responsibilities;
• Requirements for review of risk management activities;
• Requirements for collecting and reviewing production and
post-production information;
• Criteria for risk acceptability.
ISO 14971 is not specific to the development of medical
device software. As a result, it can be difficult to apply it to
the development of medical device software. Consequently,
IEC produced a Technical Report (TR) providing guidance to
medical device manufacturers on applying ISO 14971. This
guidance document is known as IEC/TR 80002-1:2009 – Part
1: Guidance on the application of ISO 14971 to medical
device software [32]. IEC/TR 80002-1:2009 follows the same
structure as ISO 14971, making it easier to follow for those
familiar with ISO 14971’s structure.
III. MOBILE MEDICAL APPLICATIONS
A. When is an App a Mobile Medical App?
A mobile application is defined as standalone software that
exists on a smart device such as a mobile phone or tablet [8].
Table I shows a number of key terms and definitions relevant
to mobile applications:

TABLE 1
KEY TERMS AND DEFINITIONS [8]
Term
Definition
Native
Software that comes pre-installed on a mobile
device such as Google Fit.
Downloadable
Software that is not pre-installed on a device
but can be downloaded and installed from
another sources.
Web-Based
An application that is accessed via a mobile
device however no installation or download
occurs to the mobile device.
Mobile
An online portal which facilities the searching
Application
for, and downloading of downloadable mobile
Store
application e.g. App store or Google Play.
Mobile Device
The primary operating system, which resides
OS
on a mobile device e.g. IOS or Android.

The FDA Mobile Medical Applications, Guidance for
Industry and Food and Drug Administration Staff [33] defines
a mobile medical application as:
“a mobile medical application is a mobile app that
meets the definition of a device in section 201(h) of the
Federal Food, Drug, and Cosmetic Act; and either is
intended:
• To be used as an accessory to a regulated medical
device; or
• To transform a mobile platform into a regulated
medical device.”
The FDA recognized that the definition could cause
confusion and as such, they went on further to explain that the
intended use of the mobile application would determine
whether or not it meets the definition of being a “device”. For
example, if a mobile application developer makes an app that
turns on a mobile device’s flash for the purpose of a torch for
general use, then this app is not defined as being a medical
device. However, if the app developer through marketing and
labeling intended the app for use by clinicians to assist with
their daily tasks, then this application would meet the
definition of being a “device”.
In instances such as this, the labeling and marketing would
establish the intended use, as the app could potentially be used
within multiple domains. However, where apps have been
developed with a clear medical focus but have not been
labeled and marketed for medical use, then this app would still
meet the definition of being a device as no ambiguity
surrounds the intended use. For example, if an app developer
created an app that helped analyze ECG results then regardless
of labeling, this app would be subject to regulatory controls.
Prior to the FDA releasing its draft guidance on mobile
medical applications, app developers were avoiding any form
of regulatory control by labeling their apps as lifestyle apps.
This loophole has now been closed.
B. Who is a Mobile Medical Application Manufacturer?
In other domains it may be clear who the developer of a
specific software product is i.e. the software development
organization producing a software package would be deemed
the manufacturer. However, in line with other medical device
regulations, confusion initially arose as to who was defined as
being a mobile medical application manufacturer. In the
production of other forms of medical devices such as infusion

pumps and CT scanners, FDA 21 CFR Parts 803 [34], 806
[35], 807 [36] and 820 [16], defined the definition of the
manufacturer. This definition of a manufacturer includes
anyone who:
- Develops specification;
- Designs;
- Labels;
- Creates a software system or application for a regulated
medical device.
With the release of the FDA final guidance on mobile
medical applications, the ambiguity surrounding who is
defined as a manufacturer has now been removed. Certainty
has also been provided in that distributors of MMAs do not
meet the definition of being manufacturers and as such avoid
regulatory scrutiny i.e. the Apple App Store and Google Play
Store do not need to apply for regulatory approval prior to
distributing MMAs.
TABLE II
CATEGORIES OF MMAS BY THE FDA [4]
Applications
Example
Consideration
Functionality
High Risk – good
As an extension of
Display of medical
resolution of the
approved medical
images X-Rays and
screen is extremely
device including
MRI, graphic data
important in certain
displaying, storing,
such as EEG
cases like X-Ray/MRI
analyzing, or
waveforms, bedside
as lower resolution
transmitting patient
monitors
may affect clinical
specific data
decision negatively
Converting
phone/smart
High Risk – readings
watches into urine
Applications that
may directly affect
analyzers or
convert a mobile
the clinical decisions
glucometers.
platform into a
therefore the apps
Attachment of
medical device
need to be extremely
transducers to make
accurate.
stethoscopes,
spirometers
Medium Risk – The
Applications/Websites
geographic region is
diagnosing &
Prognosis of the
very important. If a
recommending
disease, treatment
drug is not available
treatment options on
options, dosage
over the counter and
the basis of patient
calculators
patients need a
specific input
prescription then its
low risk.
Low Risk –
Marketing claims are
critical for products to
be placed in general
BMI Calculators,
health benefits
Apps for general
heart rate monitors,
category, which is
health applications &
thermometers,
very low risk, most
education purposes
medication
health applications for
reminders
mass public
consumption are
likely to fall under
this category

C. Mobile Medical Application Safety Classification
As with all software or devices used in connection with
patient care, once a mobile application meets the definition of
being a mobile medical application it must be classified as
Class I, Class II or Class III. As discussed previously, all
mobile medical applications initially are classified as Class I

devices if they meet the definition of being an MDDS, or as a
Class III device until reclassified by the FDA.
The FDA as part of its guidance has also covered guidance as
to MMAs, which it intends to exercise enforcement
discretion2. Examples include apps which:
- Help patients self-manage their disease of conditions;
- Provide patients with simple tools to organize and track
their health information;
- Provide easy access to information related to patients’
health;
- Automate simple tasks for health care providers i.e.
MDDS.
IV. DEVELOPING MOBILE MEDICAL APPLICATIONS
A. Developing Regulatory Compliant Software
Despite not dictating a Software Development Life Cycle
(SDLC) to follow, medical device software development
organizations typically follow the V-Model [38]. It was first
presented in 1991 at the NCOSE symposium [39] and is a
variation on a SDLC which Royce presented which later
became known as the Waterfall Model [40]. The V-Model
identifies that there are different types of testing such as
modular testing and integration testing [41]. The V-Model
shows the relationship between the two sides of the
development process. This relationship is used to determine
whether the stage has been completed successfully. If a
problem occurs during the verification or validation of any one
stage, then the opposite stage on the “V” must be revisited and
if necessary, reiterated [42]. Essentially, the testing of a
product is planned in parallel with the corresponding phase of
development. This method of developing software eases the
process of achieving traceability. The FDA mandates that
traceability be an integral part of a development process [43].
Therefore, the V-Model is perceived to be the “best fit” with
the regulatory requirements. While it may be the best fit, in
practice the V-Model presents the same problems that are
associated with utilizing any sequential plan driven SDLC.
Royce, who presented the Waterfall model, stated that there
are inherent problems associated with following a sequential
lifecycle [40]. For example, as requirements are fixed at such
an early stage, it can be very difficult to introduce a change in
requirements once the project is underway. Furthermore, it can
be very difficult to capture all of the requirements at such an
early stage of a project [44]. In addition to this, any changes
introduced once a project is underway can create cost and
budget overruns [45].
B. Agile Software Development
Recognizing the inadequacies associated with plan-driven
approaches, a shift has occurred toward a more flexible or
agile approach to software development. Agile software
development was first formalized in 2001 and since then has
2

The term enforcement discretion means that even if a mobile application
may meet the definition of being a medical device, the FDA can choose not to
enforce our requirements because we determined that the risk to patients is
low – Bakul Patel, Senior Policy Advisor to the center director – CDRH and
FDA [37]

gained greater acceptance in the software development
industry. This is evident in a large scale survey of software
development organizations, conducted in 2013, which
identified that 88% organizations stated that they were
following an agile approach [46]. This is an increase from
84% in 2012 [47] and 80% in 2011 [48].
The principles of agile software development originate from
the “Agile Manifesto” [49]. In February 2001, a meeting was
held at The Lodge at Snowbird ski resort in Utah. At this
meeting, 17 people met including Kent Beck, Alistair
Cockburn, and Robert C. Martin, all very experienced in the
field of software engineering, to discuss software development
methodologies. As a result of this meeting, the agile software
development alliance emerged. The agile alliance determined
the priorities of a development project, as shown in Table III:
TABLE III
AGILE SOFTWARE DEVELOPMENT VALUES
Individuals and interactions over processes and tools;
Working software over comprehensive documentation;
Customer collaboration over contract negotiation;
Responding to change over following a plan.

In essence, agile principles place a greater importance on
the human component of a development project, rather than on
utilising a rigid plan i.e. people over processes [50].
Cursory reading of these values would appear to suggest
that agile methods are contradictory to regulatory
requirements as none of the regulatory deliverables such as
documentation are produced. Further examination of the agile
values identified that the statements on the left are deemed of
greater importance than those on the right in an agile project,
however they do not replace the items on the right. For
example, as identified by Robert Martin [50], one of the
authors of the Agile Manifesto states “Produce no document
unless it’s immediate and significant” demonstrating that as
long as there is value to be obtained by the items on the right,
they should still be produced.
Regulatory requirements have been put in place to ensure
that software produced for use in connection with patient care
is of the highest quality. Furthermore, quality is one of the
main aims of the agile software development. In agile,
software development, planning, requirements definition,
design, testing and validation are all performed, however, they
are performed over several increments which are designed to
give feedback early in a software project. This approach
allows for greater clarity and control of a software
development process, more so than traditional plan driven
approaches such as the Waterfall of V-Model. This feedback
loop can be modified to incorporate risk management, human
factors, and verification and validation that meet the FDA’s
quality system regulations.
Another example as to how agile methods may be
incompatible in the medical device domain is the difficulty
associated with incremental development. In non-regulated
software development adopting agile approaches, the software
is developed partially, examined and if necessary, reiterated.
This examination can come in the form of alpha or beta testing

or possibly release to end users with the subsequent elements
being updated based on the feedback obtained. In the medical
domain and other safety-critical domains, it is not possible to
release software into a live environment without adequate
testing and regulatory approval.
1) AAMI TIR45:2012
In October 2012, the Association for the Advancement of
Medical Instrumentation (AAMI) released a Technical
Information Report (TIR) known as AAMI TIR 45:2012
Guidance on the use of agile practices in the development of
medical device software [51]. The committee that developed
the TIR consisted of industry experts and FDA staff. AAMI
recognized the shift in the generic software development
industry towards more agile practices and the evidence
presented from successful adoption of agile practices in
medical device software development organizations. However,
they identified that the available information with regards to
the adoption of agile practices when developing medical
device software was hard to understand and the objective of
the TIR is to provide clear guidance of which practices of
agile software development are suited to the development of
medical device software. The TIR also provides
recommendations for complying with international standards
and FDA guidance documents when using agile practices to
develop medical device software.
The TIR focuses on a number of areas in which agile
software development practices are suited when developing
medical device software. These areas include:
• Planning;
• Team Structure and Collaboration;
• Product Definition and Requirements Documentation;
• Software Architecture;
• Detailed Design;
• Implementation and Unit Verification;
• Integration and Integration Testing;
• Software System Testing;
• Software Release;
• Configuration Management and Change Management;
• Corrective and Preventative Action.
The TIR successfully maps practices performed as part of
agile software development techniques to each of these stages
of development. Whilst the TIR can be seen as useful when
developing medical device software, two issues can
potentially arise. Firstly, the TIR maps agile practices to IEC
62304; IEC 62304 only provides guidance for the
development of the software portion of a medical device
system and therefore, it could be difficult to apply the TIR to
the development of standalone software. Secondly, the TIR
only provides high-level guidance as to specific agile practices
that can be used when developing medical device software.
Many more agile practices exist which could potentially be
used in the development of medical device software, but are
not included in the TIR. This TIR is not a hands-on approach
on agile methods. It provides a good discussion on what can
be done or what can’t be done with agile methods, and it

serves to reassure people who are skeptical about agile
methods. Additionally, while this TIR may not be
comprehensive in its approach, it does serve as evidence of the
changing attitude of the FDA with regards the use of agile
software development approaches when developing regulatory
compliant software.
C. Can Agile approaches be used in practice?
Rasmussen, et al. [11] detailed the successful
implementation of agile practices within Abbott Diagnostics,
the organization recognized the need to move away from a
plan-driven approach. In this implementation, Abbott
completed two projects side-by-side, one in accordance with
agile methods and the other in accordance with a plan-driven
approach. While both projects were not the same size, the
organization identified that the project completed in
accordance with agile methods made a cost saving of between
35% and 50% when compared to the plan-driven project.
Rottier and Rodrigues [12] detailed the implementation of
an agile approach within Cochlear. As with Abbott
Diagnostics, Cochlear wished to streamline their development
process by moving away from a plan-driven approach to a
more agile one. However, they quickly identified that it was
not possible to wholly adopt a single agile method, such as
Scrum or XP on its own, as no single agile method provides
sufficient guidance of each of the stages, which are necessary
when developing medical device software. This supports the
findings of Vogel [52] and Turk, et al. [53], who also
identified that no single agile method is sufficiently
comprehensive for use when developing medical/safety
critical software. Within Cochlear, it was identified that
combining an agile method such as Scrum with a plan-driven
SDLC such as the V-Model, sufficient guidance for the
development of regulatory compliant software is provided.
Spence [54] discussed the implementation of Scrum within
Medtronic. Spence identified that it is not practical to follow a
rigid plan-driven approach when developing medical device
software, as it is not possible to fully complete one stage of
development before moving on to the next, whilst ruling out
the need to revisit a stage. The research conducted by Spence
is related more to the organizational challenges associated
with implementing agile in a medical device software
development organization. Further to this, Weyrauch [55]
published research on the adoption of agile practices within
Medtronic. He builds further on the information presented by
Spence, however, the detail he presented remained closer to
the organizational impact and accommodation of agile
methods, rather than the impact agile practices had on a
software development project.
Weiguo and Xiaomin [56] presented a SDLC, which
incorporates practices with a plan-driven approach and was
implemented on a medical device software development
project. Unfortunately, the information presented by the
authors is very sparse and they do not provide enough
guidance as to how their tailored SDLC was implemented
should an organization wish to adopt their SDLC. However,
they do outline that rather than wholly adopting a single agile

method, they retained the V-Model/plan-driven approach to
produce the necessary regulatory deliverables.
While the detail included as part of each of these
implementations is sparse, commonalities can be identified.
Each of the organizations initially examined the possibility of
wholly adopting a single agile method such as Scrum or XP.
They soon realized this was not possible and as such they
integrated selected agile practices with their traditional plandriven approach. Furthermore, the selected practices typically
originated from either the Scrum or XP approaches.
V. CONCLUSIONS
The FDA does not regulate specific forms of medical
devices; rather they regulate all devices that are intended for
use in connection with patient care. While the regulations
attempt to provide clear information to device manufacturers,
ambiguity can arise when they try to apply the regulations to
specific medical device sectors such as medical device
software. As a result, the FDA has released a number of
guidance documents to help medical device software
manufacturers to navigate the regulatory process. The latest
guidance document released by the FDA is intended for MMA
manufacturers and FDA staff. This document details when a
mobile application is deemed a mobile medical application
and if so, the necessary steps, which must be taken in order to
achieve regulatory approval. These steps increase the
overhead associated with developing such apps and as such,
there is the potential to deter mobile medical application
manufacturers from entering the market, which could
ultimately lead to a reduction in competition and
advancements. This paper discussed how by adopting agile
software development techniques MMA manufacturers could
continue to develop apps which meet regulatory approval,
whilst not sacrificing the approach which they may be
accustomed i.e. producing little documentation and fast
development cycles. To achieve this, MMA manufacturers are
advised to follow a hybrid software development approach.
This hybrid approach would involve following the V-Model.
This will assist in producing regulatory deliverables along
with adopting agile practices, which will assist in promoting
development and innovation.
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